Effect of Tongxinluo Capsule Combined with Clopidogrel on the Treatment of Coronary Heart Disease
Objective To explore the curative effect of Tongxinluo capsule combined with clopidogrel in the treatment of coronary heart disease.Methods A total of 100 patients with coronary heart disease and angina pectoris admitted to Huazhong Cardiovascular Hospital in Fuwai from January 2020 to December 2022 were selected.They were randomly divided into two groups using a double-blind method.The control group received oral clopidogrel treatment in addition to conventional treatment and the observation group was treated with Tongxinluo capsules orally on the basis of the control group.The therapeutic effects,levels of pentagonin-3(PTX-3),leukocyte differentiation antigen 36(CD36),and leukocyte differentiation antigen 44(CD44)indicators,myocardial enzyme spectrum and inflammatory factor indicators,serum indicator levels,and incidence of adverse reactions between two groups of patients were compared and observed.Results The total effective rate of the study group after treatment was higher than that of the control group(P＜0.05).After treatment,the PTX-3,CD36,and CD44 levels in the study group were lower than those in the control group(P＜0.05).After treatment,the levels of lactate dehydrogenase(LDH),hydroxybutyrate dehydrogenase(HBDH),hypersensitive C-reactive protein(hs-CRP),and intercellular adhesion molecule-1(ICAM-1)were lower in both groups than those before treatment(P＜0.05).After treatment,the levels of LDH,HBDH,hs-CRP,and ICAM-1 in the study group were lower than those in the control group(P＜0.05).After treatment,the levels of sCD40L,MCP-1,and sICAM-1 in the study group were lower than those in the control group(P＜0.05).Conclusion Tongxinluo capsule combined with clopidogrel has a good therapeutic effect on coronary heart disease,which can reduce the level of myocardial zymogram and inflammatory factors and regulate the serum indexes of patients.At the same time,it has high treatment safety.
NETL
NSTL
万方数据
